Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin

Annals of Pharmacotherapy

Volumn 43, Issue 12, 2009, Pages 2108-2112

  Schutt, Amanda C ^a   Bohm, Nicole M ^b  

^a CARILION CLINIC   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Daptomycin; Endocarditis; Enterococcus; Tigecycline

Indexed keywords

ACETYLSALICYLIC ACID; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; CREATINE KINASE; CREATININE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; RIFAMPICIN; SALBUTAMOL; TIGECYCLINE; VANCOMYCIN; WARFARIN;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATE; BLOOD CULTURE; CASE REPORT; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; FEMALE; FEVER; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; THORAX PAIN; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS FAECIUM; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 72249086116     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M324     Document Type: Article

References (27)

1. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:597-599
2. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006;50:3479-3484 DOI 10.1128/AAC.00210-06
3. Rybak MJ. The efficacy and safety of daptomycin: first in a new class of antibiotics for gram-positive bacteria. Clin Microbiol Infect 2006;12:24-32. DOI 10.1111/j.1469-0691.2006.01342.x
4. Oleson FB, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000;44:2948-2953
5. Cha R, Rybak MJ. Daptomycin against multiple drug-resistant Staphylococcus and Enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis 2003;47:539-546 DOI 10.1016/S0732-8893(03)00119-6
6. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptides: intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001;45:454-459 DOI 10.1128/AAC.45.2.454-459.2001
7. Cha R, Grucz RG, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003;47:1598-1603 DOI 10.1128/AAC.47.5.1598-1603.2003 (Pubitemid 36548543)
8. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy volunteers. Antimicrob Agents Chemother 2003;47: 1318-1323 DOI 10.1128/AAC.47.4.1318-1323.2003 (Pubitemid 36368592)
9. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50:3245-3249 DOI 10.1128/AAC.00247-06 (Pubitemid 44527494)
10. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994;96:200-209 (Pubitemid 24099217)
11. Dandekar PK, Tessier PR, Williams P, et al. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 2003;52:405-411 DOI 10.1093/jac/dkg337
12. Figueroa DA, Mangini E, Amodio-Groton M, et al. Clinical safety with daptomycin at doses greater than 6 mg/kg (poster A-792). Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2007, Chicago, IL.
13. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009;49:177-180 DOI 10.1086/600039
14. Alam MM, Jimenez V. Daptomycin for the treatment of persistent VRE bacteremia and/or IE that failed to respond to current therapeutics (poster 1088.15). Presented at: 45th Annual Meeting of the Infectious Disease Society of America, October 4-7, 2007, San Diego, CA.
15. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann Pharmacother 2009;43:1211-1219 Epub 7 Jul 2009. DOI 10.1345/aph.1M085
16. Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med 2007;120(10 suppl 1):S28-33. DOI 10.1016/j.amjmed.2007.07.011
17. Arias CA, Torres HA, Singh KV, et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin- resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007;45: 1343-1346 DOI 10.1086/522656
18. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006;26:347-352 DOI 10.1592/phco.26.3.347
19. Schwartz BS, Ngo PD, Guglielmo BJ. Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding (letter)? Ann Pharmacother 2008;42:289-290 Epub 2 Jan 2009. DOI 10.1345/aph.1K548
20. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006;43:518-524 DOI 10.1086/505494
21. Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis 2007;57:459-465 DOI 10.1016/j.diagmicrobio.2006.10.007
22. Performance standards for antimicrobial susceptibility testing; seventeenth information supplement. Wayne, PA: Clinical and Laboratory Standards Institute, 2007:26(1).
23. Pankey G, Ashcraft D, Patel N. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother 2005;49:5166-5168 DOI 10.1128/AAC.49.12.5166-5168.2005
24. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004; 53:530-532 DOI 10.1093/jac/dkh104 (Pubitemid 38380256)
25. Snydman DR, McDermott LA, Jacobus NV. Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and enterococci by FIC index and timed-kill curves. J Chemother 2005;17:614-621
26. Cilli F, Aydemir S, Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against gram-positive cocci. J Chemother 2006;18:27-32.
27. Jenkins I. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007;2:343-344 DOI 10.1002/jhm.236